Fulcrum Therapeutics to Present at Upcoming Investor Meetings

Rhea-AI Summary

Fulcrum Therapeutics (NASDAQ:FULC), a clinical-stage biopharmaceutical company developing small molecules for rare genetic diseases, has announced upcoming presentations at two major healthcare investment conferences.

The company will participate in the Cantor Fitzgerald 2025 Annual Global Healthcare Conference on September 4, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. Both events will be held in New York and feature presentations from key executives including CEO Alex Sapir, CFO Alan Musso, and SVP of Early Development Iain Fraser.

One-on-one meetings with management will be available to interested investors through conference representatives.

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will attend and present at the following investor conferences:

Cantor Fitzgerald 2025 Annual Global Healthcare Conference

• Location: New York, NY, U.S.
• Date: September 4, 2025
• Time: 1:35-2:05 PM ET
• Type: Fireside chat
• Presenters: Alex Sapir, Chief Executive Officer; Alan Musso, Chief Financial Officer; Iain Fraser, Senior Vice President of Early Development
• Webcast: Link

H.C. Wainwright 27th Annual Global Investment Conference

• Location: New York, NY, U.S.
• Date: September 9, 2025
• Time: 2:00-2:30 PM ET
• Type: Company presentation        
• Presenters: Alex Sapir, Chief Executive Officer; Alan Musso, Chief Financial Officer; Iain Fraser, Senior Vice President of Early Development
• Webcast: Link

Fulcrum management will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

Following the events, webcast replay links will be posted to Fulcrum Therapeutics Investor Relations’ Events and Presentations page.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

About Pociredir
Pociredir is an investigational oral small-molecule inhibitor of Embryonic Ectoderm Development (EED) that was discovered using Fulcrum’s proprietary discovery technology. Inhibition of EED leads to potent downregulation of key fetal globin repressors, including BCL11A, thereby causing an increase in fetal hemoglobin (HbF). Pociredir is being developed for the treatment of SCD. Initial data in SCD demonstrated proof-of-concept and achieved absolute levels of HbF increases associated with potential overall patient benefit. In clinical trials conducted prior to the clinical hold, which was lifted by the FDA in August 2023, pociredir was generally well-tolerated in people with SCD with up to three months of exposure, with no serious treatment-related adverse events reported. Pociredir has been granted FDA Fast Track designation and Orphan Drug Designation for the treatment of SCD. To learn more about these trials please visit ClinicalTrials.gov.

About Sickle Cell Disease
Sickle cell disease (SCD) is a genetic disorder of the red blood cells caused by a mutation in the HBB gene. This gene encodes a protein that is a key component of hemoglobin, a protein complex whose function is to transport oxygen in the body. The result of the mutation is less efficient oxygen transport and the formation of red blood cells that have a sickle shape. These sickle shaped cells are much less flexible than healthy cells and can block blood vessels or rupture cells. People with SCD typically suffer from serious clinical consequences, which may include anemia, pain, infections, stroke, heart disease, pulmonary hypertension, kidney failure, liver disease, and reduced life expectancy.

Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856

FAQ

When is Fulcrum Therapeutics (FULC) presenting at the Cantor Fitzgerald Healthcare Conference 2025?

Fulcrum Therapeutics will present at the Cantor Fitzgerald Conference on September 4, 2025, from 1:35-2:05 PM ET in a fireside chat format.

When is Fulcrum's presentation at the H.C. Wainwright Conference 2025?

Fulcrum will give a company presentation at the H.C. Wainwright Conference on September 9, 2025, from 2:00-2:30 PM ET in New York.

Who will be presenting for Fulcrum Therapeutics at the upcoming investor conferences?

The presenting team includes CEO Alex Sapir, CFO Alan Musso, and SVP of Early Development Iain Fraser.

How can investors access Fulcrum Therapeutics' conference presentations?

The presentations will be available via webcast, with replay links posted on Fulcrum Therapeutics' Investor Relations' Events and Presentations page after the events.

How can investors schedule one-on-one meetings with Fulcrum management at these conferences?

Interested investors should contact their respective representative at the sponsoring institutions (Cantor Fitzgerald or H.C. Wainwright) to request meetings.